Sale

Immunotherapy Drugs Market

Global Immunotherapy Drugs Market Size, Trends, Growth, Forecast: By Drug Class: Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha and Beta, Interleukins, Other Drugs; By Applications; By Route of Administration; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Immunotherapy Drugs Market Outlook

The global immunotherapy drugs market attained a value of USD 222.08 billion in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 11.20% to reach USD 577.42 billion by 2032.

 

Global Immunotherapy Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Incidences of Cancer to Propel the Growth of the Global Immunotherapy Drugs Industry

According to the WHO, cancer is the second leading cause of death globally, which led to nearly 10 million deaths in 2020. As a result, the governments and international organisations are increasingly conceptualising initiatives to generate funds while also spreading awareness about various types of cancer and the potential prevention strategies.

These factors are expected to drive the market growth in the coming years. Additionally, the increased expenditure in the healthcare sector and the accessibility to efficient therapeutic techniques, including target-specific and tailored treatments, are also projected to propel the global immunotherapy drugs industry further. Immunotherapy boosts the body’s natural defences to combat the disease by aiding the immune system to recognise and attack cancerous cells.

Geographically, North America is anticipated to account for a significant market share of the immunotherapy drugs industry. This can be attributed to the rising geriatric population in the region and the availability of improved medical facilities.

 

Immunotherapy Drugs: Market Segmentation

Immunotherapy is a type of biological therapy, which is used as a treatment for cancer and helps patients fight cancer by providing a boost to the immune system's natural defences to locate and attack cancer cells in the body. Some of the drugs used in immunotherapy are Ipilimumab (Yervoy®), Pembrolizumab (Keytruda®), Nivolumab (Opdivo®), and Atezolizumab (Tecentriq®), among others.

 

Global Immunotherapy Drugs Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The major types of immunotherapy drugs are:

  • Monoclonal Antibodies
  • Vaccines
  • Interferons Alpha and Beta
  • Interleukins
  • Others

The market can be broadly categorised, on the basis of therapy area, into:

  • Cancer
  • Autoimmune and Inflammatory Diseases
  • Infectious Diseases
  • Others

The EMR report looks into the regional markets of immunotherapy drugs like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Immunotherapy Drugs Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Heightened Research and Development Activities to Augment the Growth of the Global Immunotherapy Drugs Industry

The immunotherapy drugs industry is anticipated to witness growth in both developed as well as developing nations. This can be associated with the rising geriatric population and increasing incidences of chronic illnesses worldwide. Additionally, the increasing expenditure by the leading pharmaceutical companies in the research and development of efficient immunotherapy medications is estimated to propel the industry growth. Furthermore, the growing investments by the governments in the development of healthcare infrastructure are further projected to positively stimulate the market growth in the coming years. Moreover, the market is further expected to be fuelled by the rapid technological advancements in the pharmaceutical industry.

 

Key Industry Players in the Global Immunotherapy Drugs Market

The report presents a detailed analysis of the following key players in the global immunotherapy drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche AG
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Applications
  • Route of Administration
  • End User
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Monoclonal Antibodies
  • Adult Vaccines
  • Checkpoint Inhibitors
  • Interferons Alpha and Beta
  • Interleukins
  • Other Drugs
Breakup by Applications
  • Cancer
  • Autoimmune and Inflammatory Diseases
  • Infectious Diseases
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by End User
  • Hospitals
  • Specialty Centres
  • Clinics
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Abbott
  • PerkinElmer Inc.
  • Illumina, Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Allergan
  • Merck & Co., Inc.
  • Amgen Inc.
  • Thermo Fisher Scientific
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited.
  • GlaxoSmithKline plc.
  • Lupin Pharmaceuticals, Inc.
  • Lilly
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Immunotherapy Drugs Market Overview 

    3.1    Global Immunotherapy Drugs Market Historical Value (2017-2023) 
    3.2    Global Immunotherapy Drugs Market Forecast Value (2024-2032)
4    Global Immunotherapy Drugs Market Landscape
    4.1    Global Immunotherapy Drugs Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Immunotherapy Drugs Product Landscape
        4.2.1    Analysis by Drug Class
        4.2.2    Analysis by Applications
        4.2.3    Analysis by Route of Administration
        4.2.4    Analysis by End Users
5    Global Immunotherapy Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Immunotherapy Drugs Market Segmentation 
    6.1    Global Immunotherapy Drugs Market by Drug Class
        6.1.1    Market Overview
        6.1.2    Monoclonal Antibodies
        6.1.3    Adult Vaccines
        6.1.4    Checkpoint Inhibitors
        6.1.5    Interferons Alpha and Beta
        6.1.6    Interleukins
        6.1.7    Other Drugs
    6.2    Global Immunotherapy Drugs Market by Applications
        6.2.1    Market Overview
        6.2.2    Cancer
        6.2.3    Autoimmune and Inflammatory Diseases
        6.2.4    Infectious Diseases
        6.2.5    Others
    6.3    Global Immunotherapy Drugs Market by Route of Administration
        6.3.1    Market Overview
        6.3.2    Oral
        6.3.3    Parenteral
        6.3.4    Others
    6.4    Global Immunotherapy Drugs Market by End User
        6.4.1    Market Overview
        6.4.2    Hospitals
        6.4.3    Specialty Centres
        6.4.4    Clinics
        6.4.5    Others
    6.5    Global Immunotherapy Drugs Market by Distribution Channel
        6.5.1    Market Overview
        6.5.2    Hospital Pharmacy
        6.5.3    Retail Pharmacy
        6.5.4    Online Pharmacy
        6.5.5    Others
    6.6    Global Immunotherapy Drugs Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Immunotherapy Drugs Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Immunotherapy Drugs Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Immunotherapy Drugs Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Immunotherapy Drugs Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Immunotherapy Drugs Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Abbott
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    PerkinElmer Inc.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Illumina, Inc.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    QIAGEN
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    F. Hoffmann-La Roche Ltd.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Novartis AG
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    AstraZeneca
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Pfizer Inc.
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Sanofi
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Johnson & Johnson Services, Inc.
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    AbbVie Inc.
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Allergan
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    Merck & Co., Inc.
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Amgen Inc.
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    Thermo Fisher Scientific
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
    17.16    Teva Pharmaceutical Industries Ltd.
        17.16.1    Financial Analysis
        17.16.2    Product Portfolio
        17.16.3    Demographic Reach and Achievements
        17.16.4    Mergers and Acquisitions
        17.16.5    Certifications
    17.17    Takeda Pharmaceutical Company Limited.
        17.17.1    Financial Analysis
        17.17.2    Product Portfolio
        17.17.3    Demographic Reach and Achievements
        17.17.4    Mergers and Acquisitions
        17.17.5    Certifications
    17.18    GlaxoSmithKline plc.
        17.18.1    Financial Analysis
        17.18.2    Product Portfolio
        17.18.3    Demographic Reach and Achievements
        17.18.4    Mergers and Acquisitions
        17.18.5    Certifications
    17.19    Lupin Pharmaceuticals, Inc.
        17.19.1    Financial Analysis
        17.19.2    Product Portfolio
        17.19.3    Demographic Reach and Achievements
        17.19.4    Mergers and Acquisitions
        17.19.5    Certifications
    17.20    Lilly
        17.20.1    Financial Analysis
        17.20.2    Product Portfolio
        17.20.3    Demographic Reach and Achievements
        17.20.4    Mergers and Acquisitions
        17.20.5    Certifications
    17.21    Bristol-Myers Squibb Company
        17.21.1    Financial Analysis
        17.21.2    Product Portfolio
        17.21.3    Demographic Reach and Achievements
        17.21.4    Mergers and Acquisitions
        17.21.5    Certifications
    17.22    Boehringer Ingelheim International GmbH
        17.22.1    Financial Analysis
        17.22.2    Product Portfolio
        17.22.3    Demographic Reach and Achievements
        17.22.4    Mergers and Acquisitions
        17.22.5    Certifications
18    Global Immunotherapy Drugs Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global immunotherapy drugs market attained a value of nearly USD 222.08 billion.

The market is projected to grow at a CAGR of 11.20% between 2024 and 2032.

The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 577.42  billion by 2032.

The major drivers of the industry, such as the rising expenditure in the healthcare industry, rising consciousness pertaining to the availability of cancer treatments, increasing research and development activities, and rapidly growing geriatric global population, are expected to aid the market growth.

The key market trends guiding the growth of the industry include the increased prevalence of cancer cases worldwide.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The significant types of immunotherapy drugs in the industry are monoclonal antibodies, vaccines, interferons alpha and beta, and interleukins, among others.

The significant market divisions, based on therapy areas, include cancer, autoimmune and inflammatory diseases, and infectious diseases, among others.

The major players in the industry are AbbVie Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others.

Analyst Review

The global immunotherapy drugs market attained a value of nearly USD 222.08 billion in 2023, driven by the rising prevalence of cancer and other chronic illnesses worldwide. Aided by the growing investments in the pharmaceutical industry, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 11.20%. The market is projected to reach USD 577.42 billion by 2032.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the immunotherapy drugs industry can be segmented into monoclonal antibodies, vaccines, interferons alpha and beta, and interleukins, among others. On the basis of therapy area, the industry can be classified into cancer, autoimmune and inflammatory diseases, and infectious diseases, among others. The major regional markets for immunotherapy drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include AbbVie Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER